EyeGate Pharmaceuticals reported a net loss of $13.2 million in 2017 compared with a net loss of $13.3 million the previous year, according to a press release.
Research and development expenses increased from $8.4 million in 2016 to $10.3 million in 2017, which was attributed to an increase in clinical activity related to the phase 2b trial of its post-cataract surgery inflammation and pain treatment.
General and administrative expenses decreased by $1 million to $4.6 million for the year, due to lower professional fees.
Revenue totaled $0.408 million in 2017 (Read more...)
Uncategorized